Jan 21, 2018
New Breakthrough Drug Canakinumab Slashes Heart Attack and Cancer in Clinical Trial
Posted by Brady Hartman in categories: biotech/medical, life extension
In last years CANTOS trial, the anti-inflammatory drug Canakinumab reduced heart attacks 25% and cancer by 50%.
(Part of the look back at the best of 2017)
Summary: The drug Canakinumab reduced heart attacks by 25% and cancer by 50% by reducing chronic inflammation, according to the authors of the recent CANTOS trial. [This report was originally published on LongevityFacts on Aug 27, 2017, and has been updated. Author: Brady Hartman]